Avoid common mistakes on your manuscript.
POEMS syndrome [1] is a rare paraneoplastic syndrome caused by clonal plasma cells or lymphoplasmacytic cells causing polyneuropathy, organomegaly, endocrinopathy/edema, and monoclonal-paraprotein. Most clinical and histopathologic findings can be explained by massive vascular endothelial growth factor (VEGF) secretion [2]. NETosis is a program for formation of neutrophil extracellular traps (NETs), which consist of release of decondensed chromatin and granular contents extracellularly from granulocytes and monocytes. Here, we demonstrate leukocytoclastic vasculitis and NETosis in the bone marrow of an 80-year-old patient with POEMS syndrome. This report represents, to the best of our knowledge, the first published case of leukocytoclastic vasculitis and NETosis in POEMS syndrome and supports the role of VEGF in this phenomenon.
The patient presented with lower back pain, fatigue, and monoclonal gammopathy of undetermined significance; IgA lambda type (MGUS) was noted.
Polyneuropathy (dysesthesia, abnormal electroneuronography), papilledema, type II diabetes, metabolically active sclerotic bone lesions (Fig. 1a), enlarged lymph nodes, type B symptoms, but no hepatosplenomegaly or skin lesions were found clinically. Laboratory findings included elevated CRP (80 mg/l) and significantly elevated VEGF levels of > 2000 pg/ml (normal < 380 pg/ml).
Iliac crest biopsy histologically (Fig. 1b) apparently captured one of the osteosclerotic foci revealed by positron emission tomography-computed tomography (PET-CT) (Fig. 1a), as peripheral blood counts were near normal apart from mildly elevated thrombocytes (400 g/l). Myofibroblast proliferation (Fig. 1b, SMA) and osteosclerosis with broadening of unmineralized osteoid activated osteoclasts, osteoblasts, and increased macrophages (Fig. 1b, CD68) were seen, reminiscent of osteomyelitis and distinct from myelofibrosis in myeloproliferative neoplasms. Osteosclerotic inflammatory lesions within ischemic medullary areas contained lymphocytes admixed with IgA + lambda restricted plasma cells (Fig. 1b, CD20, IgA).
Polyneuropathy, MGUS, sclerotic bone lesions, and elevated VEGF levels were defined as major, endocrinopathy, thrombocytosis, and lymphadenopathy as minor criteria according to the IWMG [1] for POEMS syndrome. Therapy composed of dexamethasone p.o. and bortezomib s.c. for six cycles led to a significant reduction of VEGF levels to 705 pg/ml, normalization of platelet counts and CRP, and reduced metabolic activity of the bone lesions, weight gain, and less fatigue.
Within the bone marrow leukocytoclastic vasculitis and focal NETosis was demonstrated (Fig. 1b, c). By immunofluorescence, pockets of neutrophils and distorted nuclei (DAPI) colocalizing with neutrophil elastase (NE) and DNA-histone (Fig. 1c, white arrows) supported NETosis in situ.
Leukocytoclastic vasculitis is a hypersensitivity vasculitis. It occurs as a complex series of endothelial/leukocyte interactions, vascular dilation, and leakage. Deposition of immune complexes and C3 around blood vessels is involved in the damage to endothelial cell membranes [3]. Interestingly, in patients with leukocytoclastic vasculitis in the skin, VEGF serum levels are also elevated [4]. One explanation for degranulation of mature neutrophils, NETosis, and leukocytoclastic vasculitis in POEMS may be via phosphorylation of ERK (extracellular-signal regulated kinases) downstream of VEGF receptor 1/flt1 in neutrophils [5, 6].
While in vitro NETosis is a broadly studied effect and has been demonstrated to play a pivotal role in severe COVID-19 [7], few studies have shown NETosis occurring in vivo [8]. Further studies are needed to investigate the exact mechanism of leukocytoclastic vasculitis and NETosis and whether anti-VEGF inhibition may be of therapeutic use in a subset of patients.
Data availability
Additional data is available upon request.
References
Dispenzieri A (2019) POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 94(7):812–827. https://doi.org/10.1002/ajh.25495
Gütgemann I, Stevens K, Loftus D et al (2008) VEGF and osteosclerosis in POEMS syndrome. Ann Hematol 87(3):243–245. https://doi.org/10.1007/s00277-007-0425-0
Buket Sahin E, Hapa A, Elcin G et al (2011) Leukocytoclastic vasculitis: retrospective analysis of 60 patients. Turk J Dermatol 5(4):85–91. https://doi.org/10.5152/tdd.2011.20
Viac J, Pernet I, Schmitt D et al (1999) Overexpression of circulating vascular endothelial growth factor (VEGF) in leukocytoclastic vasculitis. Arch Dermatol Res 291(11):622–623. https://doi.org/10.1007/s004030050464
Geindreau M, Ghiringhelli F, Bruchard M (2021) Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 22(9). https://doi.org/10.3390/ijms22094871
Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18(2):134–147. https://doi.org/10.1038/nri.2017.105
Veras FP, Pontelli MC, Silva CM et al (2020) SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 217(12). https://doi.org/10.1084/jem.20201129
Röhm M, Grimm MJ, D’Auria AC et al (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82(5):1766–1777. https://doi.org/10.1128/IAI.00096-14
Nowak V, Agaimy A, Kristiansen G et al (2020) Increased IgG4-positive plasma cells in nodular-sclerosing Hodgkin lymphoma: a diagnostic pitfall. Histopathology 76(2):244–250. https://doi.org/10.1111/his.13965
de Buhr N, von Köckritz-Blickwede M (2016) How neutrophil extracellular traps become visible. J Immunol Res 2016:4604713. https://doi.org/10.1155/2016/4604713
Acknowledgements
We thank A. Dispenzieri (Mayo Clinic, Rochester, MN) for helpful comments on our manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
WA, BL, MPH, HES, FG, AH, and IG contributed data; IG and HES designed the study; WA, AH, IG, and HES wrote the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Approval for publication and study was obtained from the patient and from the ethics committee of the University of Bonn, Germany (no. 236/12), according to local and national guidelines. The procedures used in this study adhere to the tenets of the Helsinki Declaration of 1975 and as revised in 2008.
Consent for publication
Consent for publication was obtained prior to submission from all co-authors.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Aderhold, W., Lenz, B., Hübner, M.P. et al. Intramedullary leukocytoclastic vasculitis and neutrophil extracellular trap (NET) formation in POEMS syndrome. Ann Hematol 103, 1415–1417 (2024). https://doi.org/10.1007/s00277-024-05651-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-024-05651-w